Pharma stock hits 5% lower circuit after EDQM and AEMPS find 4 critical observations in its manufacturing unitPharma stock hits 5% lower circuit after EDQM and AEMPS find 4 critical observations in its manufacturing unit

Introduction:

Leading pharma company’s API manufacturing facility in Mohali recently underwent a joint inspection by EDQM and AEMPS. The inspection resulted in seven observations, including four critical ones, prompting the company to implement corrective measures to ensure compliance with EuGMP standards.

Also Read: Bank stock hits 20% lower circuit after it faces ₹2,000 Cr decline in its net worth

Share price movement of Nectar Lifesciences:

On March 11, 2025, Nectar Lifesciences Ltd. opened at ₹26.38, down 4.97% from its previous close of ₹27.76. The stock remained at ₹26.38 throughout the session, hitting a low and high of ₹26.38. By 10:41 AM, it traded at ₹26.38, with a market cap of ₹591.60 crore.

Nectar Lifesciences Faces EU Regulatory Hurdle After Inspection:

Nectar Lifesciences Limited’s API manufacturing facility in Mohali, Punjab, recently underwent a joint inspection by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and the Spanish Agency of Medicines and Medical Devices (AEMPS). The inspection aimed to assess compliance with EuGMP standards.

Following the inspection, regulators identified seven observations, including four critical ones, raising concerns about adherence to Good Manufacturing Practices. The company is actively preparing a Corrective Action and Preventive Action (CAPA) report to address these findings and ensure compliance with stringent regulatory norms.

Nectar Lifesciences emphasized its commitment to quality and compliance, stating that the European regulators will conduct a re-inspection after CAPA submission. The outcome of this review will determine the facility’s EuGMP approval, which is crucial for maintaining access to European markets.

Ace investor holding in Nectar Lifesciences:

Jaideep Sampat 

Jaideep Sampat holds a 2.07% stake in Nectar Lifesciences Ltd., owning 4,646,924 shares valued at ₹12.3 crore. His investment reflects confidence in the company’s prospects despite recent regulatory challenges affecting its stock performance.

Stock performance of Nectar Lifesciences for Period of 1 week, 6 months, and 1 year:

Nectar Lifesciences Ltd. saw a 5.87% gain over the past week, but remains under pressure with a 48.5% decline in six months and an 18.1% drop over the past year, reflecting ongoing challenges despite short-term recovery.

Also Read: Tata group stock jumps 3% after company to invest ₹49,000 Cr in Andhra Pradesh for renewable energy projects

Shareholding pattern of Nectar Lifesciences:

Particulars	Dec 2024	Sep 2024	Jun 2024
Promoter	44.50%	55.80%	55.80%
FII	0.70%	3.20%	16.60%
DII	0.00%	0.00%	0.00%
Public	54.70%	40.90%	27.60%

About Nectar Lifesciences:

Nectar Lifesciences Ltd. (NSE: NECLIFE), incorporated in 1995, is a research-driven manufacturer of APIs, intermediates, and formulations, specializing in anti-infectives like Cephalosporins. It also operates as a contract manufacturing organization (CMO) for global pharmaceutical innovators.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.